A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Basic science
Enrollment
8actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-13 | actual | When the study began enrolling |
| Primary completion | 2025-12-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-16 | actual | The whole study's end, after follow-up |
| First posted | 2026-02-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adult Participants
Interventions
- Drug: Oral [14C] PF-07248144
- Drug: Oral unlabeled PF-07248144
- Drug: IV [14C] PF-07248144
Primary outcomes
what the primary-completion date above is the date OFTotal recovery of radioactivity in urine, feces and vomitus (if any) expressed as a percent of total radioactive dose administered.
measured Period 1 pre-dose to maximum Days 22
Metabolic profiling/identification and determination of relative abundance of [14C]PF-07248144 and the metabolites of [14C]PF-07248144 in plasma, urine, and feces.
measured Period 1 pre-dose to maximum Days 22
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed